SCHEMBL20942203

SCHEMBL20942203

Cn1cc(C(=O)Nc2ccc3c(c2)CCCO3)c2ccccc2c1=O

nearest known ligand 0.53

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ TAF1 P21675 1/20 0.49
▸ BRD4 O60885 5/20 0.49
▸ L3MBTL1 Q9Y468 1/20 0.46
▸ POLB P06746 1/20 0.46
▸ RAB9A P51151 4/20 0.46
▸ MAOB P27338 2/20 0.45
▸ MAPT P10636 3/20 0.44
▸ NPC1 O15118 3/20 0.44
▸ TP53 P04637 1/20 0.44
▸ TSHR P16473 1/20 0.44
▸ SMN1; SMN2 Q16637 1/20 0.44
▸ ALDH1A1 P00352 3/20 0.44
▸ KDM4E B2RXH2 1/20 0.44
▸ LMNA P02545 1/20 0.44
▸ HPGD P15428 1/20 0.44
▸ HSD17B10 Q99714 1/20 0.44
▸ MITF O75030 1/20 0.44
▸ THRB P10828 1/20 0.44
▸ NPSR1 Q6W5P4 1/20 0.44
▸ USP2 O75604 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL20942536 0.89 TAF1 (0.60) TAF1BRD4RAB9AMAPTNPC1
SCHEMBL30402413 0.86 TAF1 (0.65) TAF1BRD4RAB9AMAPTNPC1
SCHEMBL20942542 0.86 TAF1 (0.65) TAF1BRD4RAB9AMAPTNPC1
SCHEMBL20942538 0.82 NPC1 (0.60) TAF1BRD4RAB9AMAPTNPC1
SCHEMBL20942626 0.81 TAF1 (0.76) TAF1RAB9AMAOBMAPTNPC1
SCHEMBL19276494 0.76 NPC1 (0.58) BRD4L3MBTL1POLBRAB9ANPC1
SCHEMBL20942558 0.76 TAF1 (0.60) TAF1RAB9AMAPTNPC1TP53
SCHEMBL19276574 0.74 BRD4 (0.52) BRD4L3MBTL1POLBRAB9AMAPT
SCHEMBL19276575 0.73 BRD4 (0.60) BRD4L3MBTL1POLBRAB9AMAOB
SCHEMBL20942498 0.73 POLB (0.82) BRD4L3MBTL1POLBRAB9AMAOB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-10702518-B2 TAF1 inhibitors for the therapy of cancer CeMM—FORSCHUNGSZENTRUM FÜR MOLEKULARE MEDIZIN GmbH (AT) 2020-07-07 — — US disclosed
US-20190117641-A1 TAF1 INHIBITORS FOR THE THERAPY OF CANCER CEMM - FORSCHUNGSZENTRUM FÜR MOLEKULARE MEDIZIN GMBH (AT) 2019-04-25 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20190117641-A1 TAF1 INHIBITORS FOR THE THERAPY OF CANCER TAF1, TAF1L, TAF5 TAF1 1/4885BRD4 27/4885L3MBTL1 2669/4885
US-10702518-B2 TAF1 inhibitors for the therapy of cancer TAF1, TAF1L, TAF5 TAF1 1/4885BRD4 27/4885L3MBTL1 2669/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback